A Phase 2 interventional study of Nivolumab and Low dose Cyclophosphamide (CTX) Daily in Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome, sponsored by Masonic Cancer Center, University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-26.
Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing nivolumab in Leukemia, Myeloid, Acute — none open to participants now, 1 under way, none of them phase 3. Nivolumab · Leukemia, Myeloid, Acute.
Among the 13 studies testing nivolumab in Leukemia, Myeloid, Acute, this one is the 9th largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 2, and was the 7th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →None of the 13 studies testing nivolumab in Leukemia, Myeloid, Acute is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 1
First in 2013; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 15 across the 13 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 7 most frequent:
Masonic Cancer Center, University of Minnesota is the lead sponsor of 286 studies on the registry; 35 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 28 (72%) have results posted.
56 studies in Leukemia, Myeloid, Acute by Masonic Cancer Center, University of Minnesota: 7 open now, 8 under way, none of them phase 3. Of 42 finished, 27 (64%) have results posted.
Among the 56 studies in Leukemia, Myeloid, Acute by Masonic Cancer Center, University of Minnesota, this one is the 34th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2018, is one of 30 in phase 2, and was the 43rd registered.
Masonic Cancer Center, University of Minnesota’s Leukemia, Myeloid, Acute studies by the year they started, since 1996.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing nivolumab in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Masonic Cancer Center, University of Minnesota’s 56 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) who are not eligible for or decline hematopoietic stem cell transplant. It includes a randomized pilot sub-study during stage 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets one of the following disease criteria:
Adequate organ function within 14 days of study registration defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nivolumab · Drug: Low dose Cyclophosphamide (CTX) Daily
Drug: Nivolumab · Drug: Low dose Cyclophosphamide (CTX) Every 7 Days
3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
Also known as: Opdivo
Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
Also known as: CTX
Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
Also known as: CTX
Stage 1: Dosing Schedule of Low-dose Cyclophosphamide
Number of participants with adverse events
Time frame: 4 weeks from start of treatment
Clinical Benefit and Immunologic Response of the Combination Therapy
Overall response rate at 90 days from treatment start. Response is defined as CR + CRi + CRp + PR in AML and CR/PR/hematologic improvement (HI) in MDS. Complete Remission (CR) - subjects must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state, an ANC \> 1 x 109/L and platelet count ≥ 100 x 109/L and normal marrow differential with \< 5% blasts, and they will be RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There should be no evidence of extramedullary leukemia Complete Remission with Incomplete Hematologic Recovery (CRi) - subjects must fulfill all the criteria for CR except for incomplete hematological recovery Complete Remission with Incomplete Platelet Recovery (CRp) - subjects must achieve CR except for incomplete platelet recovery Partial Remission (PR) - subjects must have ≥50% bone marrow blast reduction or decrease to 5 to 25%
Time frame: 90 days from start of treatment
Objective Response Rate (ORR)
Incidence of overall response.
Time frame: 30 days from start of treatment
Progression Free Survival (PFS)
Incidence of progression free survival.
Time frame: 6 months from start of treatment
Overall Survival (OS)
Incidence of overall survival.
Time frame: 6 months from start of treatment
| Milestone | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days |
|---|---|---|
| Started | 6 | 6 |
| Completed | 0 | 0 |
| Not completed | 6 | 6 |
Number of participants with adverse events
| Participants | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days |
|---|---|---|
| Stage 1: Dosing Schedule of Low-dose Cyclophosphamide | 6 | 6 |
Overall response rate at 90 days from treatment start. Response is defined as CR + CRi + CRp + PR in AML and CR/PR/hematologic improvement (HI) in MDS. Complete Remission (CR) - subjects must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state, an ANC \> 1 x 109/L and platelet count ≥ 100 x 109/L and normal marrow differential with \< 5% blasts, and they will be RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There should be no evidence of extramedullary leukemia Complete Remission with Incomplete Hematologic Recovery (CRi) - subjects must fulfill all the criteria for CR except for incomplete hematological recovery Complete Remission with Incomplete Platelet Recovery (CRp) - subjects must achieve CR except for incomplete platelet recovery Partial Remission (PR) - subjects must have ≥50% bone marrow blast reduction or decrease to 5 to 25%
| Participants | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days |
|---|---|---|
| Clinical Benefit and Immunologic Response of the Combination Therapy | 0 | 0 |
Incidence of overall response.
| Participants | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days |
|---|---|---|
| Objective Response Rate (ORR) | 0 | 0 |
Incidence of progression free survival.
| Participants | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days |
|---|---|---|
| Progression Free Survival (PFS) | 0 | 0 |
Incidence of overall survival.
| Participants | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days |
|---|---|---|
| Overall Survival (OS) | 4 | 5 |
Collected over Adverse events were collected from on treatment date up until 6 months after the off treatment date, on average of 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | 2/6 (33.3%) | 3/6 (50%) | 4/6 (66.7%) |
| Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days | 1/6 (16.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Event | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days |
|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specifyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 2/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/6 | 2/6 |
| Lung infectionInfections and infestations | 1/6 | 1/6 |
| Event | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days |
|---|---|---|
| GI DisordersGastrointestinal disorders | 3/6 | 6/6 |
| Edema limbsGeneral disorders | 2/6 | 3/6 |
| Age, Categorical(Participants) | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 2 | 5 |
| >=65 years | 3 | 4 | 7 |
| Sex: Female, Male(Participants) | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 6 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily | Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Jan 2022, 41 months.
Results were first posted in May 2023, 1 year 4 months after primary completion.
Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's 41 months is below that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Masonic Cancer Center, University of Minnesota →